Title: "A Phase 3, Multicenter, Randomized Study to Evaluate the Substitution of Marqibo (Vincrisitne Sulfate Liposomes Injection, VSLI) for Standard
Vincristine Sulfate Injection (VSI) in the Induction, Intensification, and Maintenance Phases of Combination Chemotherapy in the Treatment of Subjects greater than or equal to 60 Years Old with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)."
Vincristine sulfate, as a single agent given IV once weekly, 4-8 doses is most common treatment protocol for TVT.
Marqibo is a novel, targeted, Optisome(TM) encapsulated formulation of
vincristine sulfate, a widely-used chemotherapy, which has shown promising anti-cancer activity in patients with ALL, non-Hodgkin's lymphoma, Hodgkin's disease, and melanoma in several clinical trials.
Treatment was started with
Vincristine sulfate 0.5 mg/[m.sup.2].
United States-based CASI Pharmaceuticals' import drug registration application for MARQIBO (
vinCRIStine sulfate LIPOSOME injection) has been accepted for review by China's Food and Drug Administration, it was reported yesterday.
Hana Biosciences (OTCBB:HNAB), South San Francisco, a biopharmaceutical company focused on strengthening the foundation of cancer care, has announced data from its pivotal Phase 2 rALLy clinical trial for Marqibo(R) (
vincristine sulfate liposomes injection) for the treatment of adult acute lymphoblastic leukemia (ALL) in second relapse.